Hidehito HORINOUCHI· @HHorinouchi · X·· 23 hours agoScore70
Body · original
🆙#ESMO26 Rapid Oral I: #LCSM Mets
🔥Overall Survival (OS) Analysis of Telisotuzumab Adizutecan in Patients (Pts) With Nonsquamous Non-Small Cell Lung Cancer (NSQ NSCLC): Phase 1 First-in-Human Study
🎙️Dr. David Sommerhalder
🔢2658RO
🎯Median OS 13.8mo (EGFR WT, n=48) and 16.2mo (EGFR MUT, n=41) in Heavily Pretreated Pts
🎯Longer OS in High c-Met Expressers (25.2mo, EGFR WT ≥3+/≥10%)
☑️NCT05029882
🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255
@OncoAlert @Larvol @myESMO @IASLC
90 views · 3 likes · 3 reposts · 0 replies
Conference abstracts
2658ROmatched by Rapid oral 1: NSCLC, metastatic
Overall survival (OS) analysis of telisotuzumab adizutecan in patients (pts) with nonsquamous non-small cell lung cancer (NSQ NSCLC): Phase 1 first-in-human study
https://esmocongress.esmo.org🆙#ESMO26 Rapid Oral I: #LCSM Mets 🔥Overall Survival (OS) Analysis of Telisotuzumab Adizutecan in Patients (Pts) With Nonsquamous Non-Small Cell Lung Cancer (NSQ NSCLC): Phase 1 First-in-Human Study 🎙️Dr. David Sommerhalder 🔢2658RO 🎯Median OS 13.8mo (EGFR WT, n=48) and 16.2mo (EGFR MUT, n=41) in Heavily Pretreated Pts 🎯Longer OS in High c-Met Expressers (25.2mo, EGFR WT ≥3+/≥10%) ☑️NCT05029882 🔗 https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal/show/session/255 @OncoAlert @Larvol @myESMO @IASLC在 X 查看被引用的帖子
Source: Hidehito HORINOUCHI · x.com